Abstract: The present invention provides a completely novel molting hormone receptor, which is used for efficiently screening a substance that can be applied to a disinfestant or the like. An insect molting hormone receptor comprising the following polypeptide (a) and polypeptide (b) or (c): (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1; (b) a polypeptide having the amino acid sequence shown in SEQ ID NO: 2; and (c) a polypeptide having the amino acid sequence shown in SEQ ID NO: 3.
Type:
Grant
Filed:
February 2, 2004
Date of Patent:
September 9, 2008
Assignees:
Kumiai Chemical Industry Co., Ltd., Hiromichi Nagasawa
Abstract: Proteins capable of modulating or mediating the function of MORT-1 are disclosed. Also disclosed are DNA sequences encoding these proteins, the recombinant production of these proteins as well as their use.
Type:
Grant
Filed:
June 8, 2006
Date of Patent:
September 2, 2008
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
David Wallach, Yura Goltsev, Andrei Kovalenko, Eugene Varfolomeev, Vadim Brodianski
Abstract: Isolated apoptosis inducing receptors, DNAs encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors thereof.
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
August 26, 2008
Assignee:
Immunex Corporation
Inventors:
Mariapia A. Degli-Esposti Rankin, Raymond G. Goodwin
Abstract: A gene coding for any of the following estrogen receptors (a) to (c): (a) an estrogen receptor comprising the amino acid sequence represented by amino acid numbers 153 to 602 in the amino acid sequence of SEQ ID NO: 1, (b) an estrogen receptor comprising the amino acid sequence of SEQ ID NO: 1, and (c) an estrogen receptor comprising an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence represented by amino acid numbers 153 to 602 in the amino acid sequence of SEQ ID NO: 1; and the like.
Abstract: Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
Abstract: The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.
Abstract: Taste receptor polycystin-2L1 is provided. Methods and systems for screening for tastants and receptor modulators are provided. Knock out and transgenic animals, methods of detecting polymorphisms, and methods of correcting taste defects are also provided.
Type:
Grant
Filed:
July 6, 2005
Date of Patent:
August 5, 2008
Assignee:
The Regents of the University of California
Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.
Abstract: Methods are provided for determining the position of a post-translationally modified (PTM) amino acid residue such as a phosphorylated amino acid residue or an O-glycosylated amino acid residue in a peptide. Also provided are methods for determining the identity of a PTM amino acid residue in a peptide. In addition, kits for practicing such methods are provided.
Abstract: The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. The concept detailed herein involves novel mutants of G-CSF, using single substitutions to amino acids, which were rationally chosen to affect the cellular trafficking of G-CSF and/or G-CSFR. In addition, pharmaceutical compositions, and methods of use are provided.
Type:
Grant
Filed:
January 31, 2005
Date of Patent:
July 22, 2008
Assignee:
Massachusetts Institute of Technology
Inventors:
Casim A. Sarkar, Douglas A. Lauffenburger, Bruce Tidor
Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
Type:
Grant
Filed:
November 27, 2006
Date of Patent:
July 8, 2008
Assignee:
INCYTE Corporation
Inventors:
Roger T. Coleman, Olga Bandman, Craig G. Wilde
Abstract: Human G-protein parathyroid hormone (PTH) receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the PTH receptor receptor polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the PTH receptor receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host. Disclosed embodiments of the invention also include antibodies that bind Human G-Protein parathyroid hormone (PTH) receptor polypeptides and methods for making and using such antibodies.
Type:
Grant
Filed:
August 19, 2004
Date of Patent:
July 1, 2008
Assignee:
Human Genome Sciences, Inc.
Inventors:
Daniel R. Soppet, Yi Li, Craig A. Rosen, Steven M. Ruben
Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
Type:
Grant
Filed:
December 22, 2004
Date of Patent:
June 17, 2008
Assignee:
ZymoGenetics, Inc.
Inventors:
Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker, Debra G. Gilbertson, James W. West
Abstract: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
Type:
Grant
Filed:
December 30, 2003
Date of Patent:
June 17, 2008
Assignees:
3M Innovative Properties Company, Trustees of Dartmouth College
Inventors:
Randolph J. Noelle, Cory L. Ahonen, Ross M. Kedl
Abstract: The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF and polynucleotides regulating CTGF expression. The invention also provides agents that modulate CTGF and therapeutic methods for using the agents. Also provided are diagnostic methods for using CTGF and assays for identifying agents which affect the expression of CTGF polynucleotide.
Type:
Grant
Filed:
January 7, 2003
Date of Patent:
June 10, 2008
Assignee:
University of South Florida
Inventors:
Gary R. Grotendorst, Douglass M. Bradham, Jr.
Abstract: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.
Type:
Grant
Filed:
May 26, 2006
Date of Patent:
June 3, 2008
Assignee:
Maxygen Holdings, Ltd.
Inventors:
Carsten Germansen, Bobby Soni, Grethe Rasmussen
Abstract: The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13R?) proteins, particularly canine interleuken receptor alpha 1 (IL-13R?1) and canine interleuken receptor alpha 2 (IL-13R?2) proteins. Also included are canine IgG and IL-13R? proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors.
Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 70% identical to residues 52-179 of SEQ ID NO:2 or residues 258-370 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
Type:
Grant
Filed:
March 15, 2005
Date of Patent:
May 20, 2008
Assignee:
ZymoGenetics, Inc.
Inventors:
Teresa Gilbert, Charles E. Hart, Paul O. Sheppard
Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
August 13, 2002
Date of Patent:
May 13, 2008
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
Type:
Grant
Filed:
July 19, 2005
Date of Patent:
May 13, 2008
Assignee:
Genentech, Inc.
Inventors:
Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang